Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

checkorphan
Learn more about:
Acute mountain sickness
Related Clinical Trial
Colorado-Oregon Altitude Study The Effects of Intermittent Hypoxia on Acute Hypoxic Injury Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude The Pre-acclimatization Augmented Extreme Altitude Expedition Effect of Altitude on Iron Absorption in Iron Depleted Women Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD HIGH Altitude CArdiovascular REsearch Latin America Population Study Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

Official Title

Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

Brief Summary

      This is a research study on Altitude Illness. From the information collected and studied in
      this project we hope to learn more about Altitude Illness, including factors that may affect
      and prevent the development and progression of this condition. We hope to learn if the
      commonly used non-steroidal anti-inflammatory medication, ibuprofen can prevent altitude
      illness. Possible participants in this study are healthy adults who indicated they would like
      to participate, learn about altitude illness, and desire to hike Barcroft Peak. Stanford
      University researchers hope to enroll about 100 participants.

Detailed Description

      This study was designed to bring together elements of prior studies and go one step further
      for definitive data on several points. The trial will employ two pharmaceutical intervention
      arms, which will compare placebo (the standard of care - information on prevention of
      altitude sickness) with the widely used NSAID ibuprofen. We will also determine Optic Nerve
      Sheath Diameter (ONSD) measurements via ultrasound in both the control and interventional
      arms. We will accomplish these objectives with a prospective, double blinded view of a large
      population of hikers who are ascending at their own rate in a true hiking environment: The
      White Mountain Research Station Owen Valley Lab (OVL) and Bancroft Station (BAR).

      Primary hypothesis: Ibuprofen 600 mg TID will be superior to placebo in decreasing both the
      incidence and severity of AMS in high altitude travel.

Study Phase

Phase 3

Study Type

Interventional

Primary Outcome

Acute Mountain Sickness

Condition

Altitude Sickness

Intervention

Ibuprofen

Study Arms / Comparison Groups

 ibuprofen
Description:  600mg ibu TID

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

89

Start Date

July 2010

Completion Date

August 2010

Primary Completion Date

August 2010

Eligibility Criteria

        Inclusion Criteria:

          1. Healthy Male or female volunteer

          2. Age 18-65

          3. Sea-level dwelling

          4. Non pregnant

          5. Have not been to high altitude in the past week

          6. Can arrange for their own transportation to WMRS by friday evening the weekend of
             their study enrollment and are available the duration of the weekend of their study
             enrollment

        Exclusion Criteria:

          1. Age <18 or >65

          2. Live at altitude > Sea Level +/- 1000'

          3. Pregnant

          4. Taking NSAIDs, Acetazolamide, or Corticosteroids

          5. Allergic to NSAIDs or Aspirin, or have had adverse reaction to them in the past

          6. Traveled or planning to travel to high altitude in the week prior to their enrollment.

          7. Medical history of Brain Tumor, increased intercranial pressure, pseudotumor cerebri,
             ventricular shunts, loss of an eye, Asthma, HACE or HAPE.

          8. Cannot arrange for their own transportation to WMRS or are unavailable for the
             duration of the weekend of their study enrollment

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Grant S Lipman, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT01171794

Organization ID

SU-12012009-4443

Responsible Party

Principal Investigator

Study Sponsor

Stanford University

Collaborators

 University of California, San Diego

Study Sponsor

Grant S Lipman, Principal Investigator, Stanford University

Verification Date

November 2018